박테리오파지 시장 : 현황 분석과 예측(2022-2028년)

Bacteriophages also known as phage viruses are a group of viruses, that infect and replicate inside bacteria. They are the most abundant biological entities on Earth and play an important role in regulating bacterial populations in various environments. Phages have been used as a therapeutic agent for treating bacterial infections, and they also have potential applications in biotechnology and biodefense.

The bacteriophage market is anticipated to grow with a CAGR of 4.5%. This is attributed to the increase in the prevalence of developing antibiotic resistance amongst patients globally. For instance, according to the Centre for disease control and Prevention's December 2021 report, around the United States, more than 2.8 million anti-microbial infections occur each year. Additionally, as bacteria become increasingly resistant to antibiotics, there is a growing need for alternative treatments. Bacteriophages may offer a solution as they can specifically target and kill bacteria without harming humans or other organisms. Further, bacteriophages can be tailored to specific bacterial strains, which may make them more effective than traditional antibiotics. Thus, the above-mentioned elements are anticipated to boost market growth.

Based on product type, the market is bifurcated into pre-biotic and pre-therapeutics. Amongst this, the pre-biotic segment is anticipated to grow with a significant CAGR in the forecasted period. Pre-biotics can help to promote the growth of bacteriophages, which can help to reduce the number of harmful bacteria in the gut and improve overall health. Therefore, the pre-biotic segment is expected to benefit from the growth of the bacteriophage market. Thus, this above-mentioned factor is anticipated to fuel the market growth in the forecasted period.

Based on the application type, the market is segmented into the gastrointestinal tract, respiratory tract infection, urinary tract infections and others. Amongst this, the respiratory tract infection segment is anticipated to grow with a significant CAGR in the forecasting period. This is attributed to the rising incidence of pneumococcal disease, caused by the bacteria streptococcus pneumonia. For instance, according to the Centre for disease control and Prevention 2019 report, more than 30 million pneumococcal infections occur each year in the United States, amongst this in more than 30% of infections, the bacteria are resistant to one or more clinically relevant antibiotics. This element is driving the market demand for bacteriophage.

Based on the route of administration, the market is segmented into oral, topical and parenteral routes. Amongst these, the oral route of administration is anticipated to grow with a significant CAGR during the forecasting period. oral route of drug administration is preferred and is the most convenient route of drug administration due to its high patient compliance and cost-effectiveness. Additionally, the oral route drugs are flexible in design and production process and have fewer sterility constraints contrary to other routes of administration. Thus, these above-mentioned factors are fueling the growth of the market.

For a better understanding of the market adoption of the Behavior Health industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is attributed to the increase in healthcare expenditure in this region. For instance, healthcare expenditures paid to medical institutions in fiscal 2021 reached a record USD 316 trillion, an increase of 14 trillion, or 4.6%, compared to the previous year. This is propelling the market growth in this region.

Some of the major players operating in the market include: Armata Pharmaceuticals, Inc., Life Extension., Arthur Andrew Medical., Biochimpharm, Micreos, biostation., Probiotic America, LLC., Eliava BioPreparations, Locus Biosciences, Inc., BiomX.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Bacteriophage Market
• 2.2. Research Methodology of the Bacteriophage Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL BACTERIOPHAGE MARKET COVID-19 IMPACT

6 GLOBAL BACTERIOPHAGE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Phage Pro-biotic
• 7.2. Phage Therapeutics

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Gastrointestinal tract
• 8.2. Respiratory Infection Treatment
• 8.3. Urinary Tract Infection
• 8.4. Others

9 MARKET INSIGHTS BY END-USERS

• 9.1. Oral
• 9.2. Topical
• 9.3. Parenteral

10 MARKET INSIGHTS BY REGION

• 10.1 North America Market
  • 10.1.1 U.S.
  • 10.1.2 Canada
  • 10.1.3 Rest of North America
• 10.2 Europe Market
  • 10.2.1 UK
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific Market
  • 10.3.1 China
  • 10.3.2. Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Rest of APAC
• 10.4 Rest of the World Market

11 BACTERIOPHAGE MARKET DYNAMICS

• 11.1 Market Drivers
• 11.2 Market Challenges
• 11.3 Impact Analysis

12 BACTERIOPHAGE MARKET OPPORTUNITIES

13 BACTERIOPHAGE MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1 Demand Side Analysis
• 14.2 Supply Side Analysis

15 STRATEGIC INSIGHTS

16 COMPETITIVE SCENARIO

• 16.1 Competitive Landscape
  • 16.1.1 Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 Armata Pharmaceuticals, Inc.
• 17.2. Life Extension.
• 17.3 Arthur Andrew Medical.
• 17.4. Biochimpharm
• 17.5. Micreos
• 17.6. biostation.
• 17.7. Probiotic America, LLC.
• 17.8. Eliava BioPreparations
• 17.9. Locus Biosciences, Inc.
• 17.10. BiomX.

18 DISCLAIMER